NOTICE OF TECHWATCH SYSTEM TRANSITION: BARDA has transitioned to new portal for stakeholder engagement, including a new TechWatch Meeting Request submission form. The new submission portal has launched and can be access on the BARDA Digital Resources Portal.
TECHWATCH IS BACK!

REQUEST A TECHWATCH MEETING WITH BARDA AND INTERAGENCY PARTNERS

BARDA is opening TechWatch again to all threat areas; including COVID-19 technologies! Submit your TechWatch Request now for the opportunity for the U.S. government experts to discuss your product, technology or capabilities and explore potential partnering opportunities.

OVER A DECADE OF INDUSTRY ENGAGEMENT

CoronaWatch Dashboard

Corona Watch Response

760+

COVID-19 CoronaWatch Virtual Market Research Meetings with innovative companies

Corona Watch Response

 

COVID-19 CoronaWatch requests from every state in the USA

Corona Watch Response

30+

Countries - CoronaWatch Meeting Requests from Around the Globe

TechWatch Dashboard

TechWatch Response

1,300+

TechWatch Market Research Meetings with innovative companies

TechWatch Response

 

TechWatch requests from every state in the USA

TechWatch Response

70+

Countries - TechWatch Meeting Requests from Around the Globe

Now coming together under a streamlined TechWatch Process

seeking submissions

The U.S. government (USG) provides a portal as a single point of entry for the submission of meeting requests from interested stakeholders with promising MCM products, technologies, and capabilities.

seeking submissions

The USG seeks information from stakeholders on available medical countermeasures in development. We are particularly interested in products, technologies, and capabilities that have progressed into or beyond clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products, technologies, or capabilities relevant to respond to public health emergencies are sought.

We ask for a brief description of your product technology, or capability, accompanied by a slide deck, manuscript, publications, or other non-confidential information of your choosing. Please note while we use information you present as market research; submission is no guarantee of a meeting or funding and your submission will be shared with our teams involved in medical countermeasure research and development. Only USG officials are invited to join TechWatch meetings and are bound by law to maintain the confidentiality of what is presented and discussed.

  • Relevant to the U.S. government medical countermeasure research and development efforts and/or Emerging Infectious Disease rapid response capabilities
  • Utilize an already-approved platform, have non-clinical data suggesting efficacy, and/or have significant manufacturing capability
  • Fully owned or licensed by your organization (you have full IP rights and/or freedom to operate)

TechWatch Meeting Process

Typically, TechWatch meeting submissions are reviewed within 30 days of submission. If your product, technology, or capability aligns with our program priorities it is likely we will contact you to set up a TechWatch meeting within an additional 30 days. Please note due to the complexities and priorities related to the pandemic slight delays in timing may result.

SELECT A STEP TO LEARN MORE

Before submitting a meeting request, you must Login. If you have not visited this site before, please take a few moments to Register.

Submit basic product information or view/update existing submissions. Upon successful submission, you will receive a confirmation email with a Tracking ID (e.g.: BDR-TW-2022-00001).

We will evaluate your request and route it to the most appropriate resource within the federal government. 
*See BARDA TechWatch Evaluation Areas for BARDA’s assessment areas.

We will schedule a targeted or broad meeting.

OR

A meeting is not scheduled, but your technology is retained for future reference.

Submit

Evaluate & Prioritize*

Notification

Before You Submit:

  • BARDA is currently evaluating TechWatch Meeting Requests for specific areas. BARDA is accepting meeting submissions for but not evaluating or granting meetings for specific areas: BARDA TechWatch Evaluation Areas.
  • These requests are for market research purposes only and are not considered submissions for potential funding.
  • Do not submit multiple requests for the same product, technology, or capability.

Before submitting a meeting request, you must Login. If you have not visited this site before, please take a few moments to Register.

Submit

Submit basic product information or view/update existing submissions. Upon successful submission, you will receive a confirmation email with a Tracking ID (e.g.: BDR-TW-2022-00001).

Evaluate & Prioritize*

We will evaluate your request and route it to the most appropriate resource within the federal government. 
*See BARDA TechWatch Evaluation Areas for BARDA’s assessment areas.

Notification

We will schedule a targeted or broad meeting.

OR

A meeting is not scheduled, but your technology is retained for future reference.

Before You Submit:

  • These requests are for market research purposes only and are not considered submissions for potential funding.
  • We are only reviewing meeting requests related to COVID-19.
  • Do not submit multiple requests for the same product or technology.

BARDA TECHWATCH EVALUATION AREAS

Explore the TechWatch submission threats and areas BARDA is actively assessing.

Threat Category
Anthrax (Bacillus anthracis)Biological
Antimicrobial Resistance / Antibiotic Susceptibility TestsBiological
Biodosimetry self-assessment toolsRad/Nuc
Botulism (Clostridium botulinum toxin)Biological
Coronaviruses (e.g., SARS, MERS, COVID-19)Biological
Epidemic/Pandemic InfluenzaBiological
Food Safety Threats (e.g., Salmonella species, Escherichia coli O157:H7, Shigella)Biological
Glanders (Burkholderia mallei)Biological
InfluenzaBiological
Meliodosis (Burkholderia pseudomallei)Biological
Plague (Yersinia pestis)Biological
Q Fever (Coxiella burnetti)Biological
Smallpox (variola major)Biological
Tularemia (Francisella tularensis)Biological
Typhus fever (Rickettsia prowazekii)Biological
Viral hemorrhagic fevers (filoviruses and arenaviruses)Biological
Water Safety Threats (e.g., Vibrio cholerae, Cryptosporidium parvum) Biological
Threat Category
DRIVe – Other SpecifyDRIVe
ENACTDRIVe
Bringing Laboratory Testing to the HomeDRIVe
Digital Health Tools for Pandemic PreparednessDRIVe
NGSDRIVe
Immune ChipDRIVe
BARDA VenturesDRIVe
DRIVe Start efforts/challengesDRIVe
ReDIRECTDRIVe
Beyond the NeedleDRIVe
Home DxDRIVe
Solving SepsisDRIVe
Rapidly Deployable CapabilitiesDRIVe
Host based therapeuticsDRIVe

Threat Category
Acute Radiation SyndromeRad/Nuc
BiotoxinsChemical
Blister Agents/VesicantsChemical
Blood AgentsChemical
Brucellosis (Brucella species)Biological
Burn/Blast InjuryRad/Nuc
Caustics (Acids)Chemical
Choking/Lung/Pulmonary AgentsChemical
Chronic Effects of Radiation ExposureRad/Nuc
Epsilon Toxin of Clostridium perfringensBiological
Incapacitating AgentsChemical
Internal ContaminationRad/Nuc
Threat Category
Long-Acting AnticoagulantsChemical
MetalsChemical
Nerve AgentsChemical
Organic SolventsChemical
Psittacosis (Chlamydia psittaci)Biological
Ricin Toxin from Ricinus communis (castor beans)Biological
Riot Control Agents/Tear GasChemical
Staphylococcal enterotoxin BBiological
Toxic AlcoholsChemical
Vomiting AgentsChemical
Zika virus diseaseBiological
  • Gain visibility for your solution
  • Receive feedback from USG experts
  • Hear techniques and strategies for addressing technical and regulatory challenges
  • Get insight on how your solution could fit within the Government
  • Better prepare you for a formal proposal submission

Note: TechWatch submissions are not considered for potential funding

  • All submissions are voluntary and are for information only. However, submitting complete information may facilitate request routing.
  • Review submitted request by Logging in and select your existing meeting request.
  • If you have additional questions about the TechWatch program, please contact us: TechWatchInbox@hhs.gov.

Note: Entities with a White Paper or proposal currently under review for any ASPR solicitation are not eligible to schedule a TechWatch meeting related to that submission. If you have concerns regarding your eligibility, please raise them with our TechWatch team as soon as possible.

  • Public Law passed by Congress and signed by the President, December 2006 (PAHPA, PAHPRA, PAHPAIA, 21st Century Cures)
  • Active outreach and scouting to improve the Nation’s public health and medical preparedness and response capabilities
  • Web based infrastructure to facilitate outreach and meetings with stakeholders
  • Key engagement function during routine and emergency operations